Ceftriaxone: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<scene name='10/1041513/Cv/2'>Transpeptidase domain of penicillin-binding protein 2 from Neisseria gonorrhoeae acylated by ceftriaxone</scene> ([[6p54]]). | <scene name='10/1041513/Cv/2'>Transpeptidase domain of penicillin-binding protein 2 from Neisseria gonorrhoeae acylated by ceftriaxone</scene> ([[6p54]]). | ||
<scene name='10/1041513/Cv/3'>Ceftriaxone binding site</scene>. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 09:30, 9 April 2024
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. It is also sometimes used before surgery and following a bite wound to try to prevent infection.[1] See also Ceftriaxone. (6p54). . |
| ||||||||||
ReferencesReferences
- ↑ "Ceftriaxone Sodium Monograph for Professionals". Drugs.com. Archived from the original on 31 May 2016. Retrieved 27 August 2016.